within Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DX10_Benralizumab;

model Benralizumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.3564814814814817e-09,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.00309,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00256,
    k12 = 2.2337962962962963e-09,
    k21 = 2.2337962962962963e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Benralizumab</td></tr><tr><td>ATC code:</td><td>R03DX10</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.09</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.29</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Benralizumab is a humanized monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα) on eosinophils, leading to their depletion. It is used for the treatment of severe eosinophilic asthma and is approved for this indication in many countries.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adults and adolescents (12–75 years) with severe eosinophilic asthma following subcutaneous administration.</p><h4>References</h4><ol><li><p>Wang, B, et al., &amp; Roskos, LK (2017). Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 6(4) 249–257. DOI:<a href=\"https://doi.org/10.1002/psp4.12160\">10.1002/psp4.12160</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28109128/\">https://pubmed.ncbi.nlm.nih.gov/28109128</a></p></li><li><p>Yan, L, et al., &amp; Roskos, LK (2019). Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma. <i>Clinical pharmacokinetics</i> 58(7) 943–958. DOI:<a href=\"https://doi.org/10.1007/s40262-019-00738-4\">10.1007/s40262-019-00738-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30854591/\">https://pubmed.ncbi.nlm.nih.gov/30854591</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03DX10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Benralizumab;
